Generated by Meeveem AI
"Developing next-generation CAR T cell therapies for cancer and autoimmune diseases"
Autolus is a CAR T cell therapy company building a fully integrated platform to deliver life-changing treatments for patients with cancer and autoimmune diseases. The company applies extensive T cell programming capabilities to develop advanced autologous therapies, with a clinical-stage pipeline for hematological malignancies, solid tumors, and autoimmune indications. Founded in 2014 on technology pioneered at University College London, Autolus has grown to encompass proprietary manufacturing processes, a modular programming approach, and strong intellectual property. The team includes pioneers in T cell therapies and leaders in cancer immunotherapies committed to developing therapies offering substantial benefits over existing treatment.
650
Team Members
2014
Founded
Biotechnology
Sector
Hybrid
Work Environment
A world where precisely programmed T cell therapies offer patients with cancer and autoimmune diseases longer, better lives with treatments that go beyond existing standards of care.
At Autolus, our mission is to bring life-saving and breakthrough therapies to patients by revolutionising medicine through the use of a patient's own cells to combat cancer and autoimmune diseases.